Table 2 : Liposomal formulated platinum-based drugs in clinical trials.


Liposomal formulation Platinum-based
drugs
Liposome Status Drug-lipid
weight ratio
MTD (mg/m2) References

Lipoplatin Cisplatin HSPC/DPPG/DSPE-PEG2000 Phase II/III 1:10 300 51~60
SPI-077 Cisplatin HSPC/cholesserol/DSPE-PEG2000 Phase II 1:70 420 61~69
LiPlaCis Cisplatin DSPC/DSPG/DSPE-PEG2000 Phase I -- -- 70
Lipoxal Oxaliplatin HSPC/DPPG/DSPE-PEG2000 Phase I -- 300 71, 72
Aroplatin NDDP DMPC/DMPG Phase II 1:15 312.5 73~79
MBP-426 Oxaliplatin TF-PEG-liposomes Phase I/II -- 226 80~82

MTD: Maximum tolerated dose; HSPC: Hydrogenated soy phosphatidylcholine; DPPG: 1,2-dipalmitoyl-sn-glycero-3-phospho-(1’-rac-glycerol).
DSPE-PEG2000: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-{methoxy(polyethylene glycol)-2000}.
DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine. DSPG: 1,2-distearoyl-sn-glycero-3-phospho-(1’-racglycerol).
DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine. DMPG: 1,2-dimyristoyl-sn-glycero-3-phospho-(1’-racglycerol).
PEG: poly(ethylene glycol). NDDP: cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II).

Ziora et al.Biochemical Compounds  2016 4:2DOI : 10.7243/2052-9341-4-2